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Abstract
Angelman Syndrome (AS) is a neurodevelopmental disorder caused by loss of the
maternal copy of UBE3A. The paternal copy cannot compensate for the loss because it
is subject to tissue-specific imprinting in the brain. This imprinting is controlled by the
reciprocal UBE3A antisense transcript (UBE3A-ATS) expressed only in the brain. The
goal of my thesis projects is to understand the underlying mechanism by which the
UBE3A-ATS is regulated. We found that UBE3A-ATS is expressed and UBE3A is
imprinted in non-neurons from an individual with 187 kb deletion at the paternal allele.
This suggests that expression of UBE3A-ATS does not require any neuronal factors,
and the regulatory elements reside in the genomic region. A minimal region consisted
of the bipartite boundary element IPW and PWAR1 is identified using CRISPR/Cas9.
Absence of this region leads to higher UBE3A-ATS expression and early UBE3A
imprinting during neural differentiation. SNRPN-PWAR1-UBE3A is in close proximity in
3D, but this interaction largely remains the same during neural differentiation. My thesis
work not only demonstrates how UBE3A-ATS is regulated, but also provides evidence
that interfering with UBE3A-ATS transcription reactivates UBE3A.
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1. Chapter 1
Chromosome 15q11-13 related disorders
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General introduction
Genomic imprinting is an epigenetic phenomenon by which genes are expressed
in a parent-of-origin dependent manner. This process occurs primarily in eutherian
mammals, although it can also be observed in plants and metatherians. The estimated
number of imprinted genes varies from a conservative estimate of 100 genes (1) to
more than 1,000 (2), depending on how such imprinted expression was ascertained and
the criteria for determining whether a gene is imprinted (3).
DNA cytosine methylation as well as specific active and repressive histone
modifications are involved in mediating the allele-specific gene expression in genes
regulated by genomic imprinting. Most imprinted loci have an imprinting control region
(ICR) that is an area of differential DNA methylation between the two parental alleles
(1). The ICR is typically methylated on the silent, repressed allele and unmethylated on
the expressed, active allele. Repressive histone modifications, such as trimethylation of
histone H3 on lysine 9 (H3K9me3) and histone H3 lysine 79 (H3K79me3), often
accompany DNA methylation on the repressed allele of the ICR (4). Active histone
modification such as di- and trimethylation of histone H3 on lysine 4 (H3K4me2 and
me3), mono- and dimethylation of histone H3 lysine 79 (H3K79me1 and me2), and
acetylation of histone H4 lysine 91 (H3K91Ac) often adorn the unmethylated allele at the
ICR (4). Altogether the ICR often controls the imprinted expression of all of the genes
within the imprinted cluster, regardless of the parent of origin of their gene expression.
Thus, the ICR harbors important epigenetic modifications that ultimately determine the
allele-specific expression of several imprinted genes within a cluster.
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Imprinted genes, which are expressed from a single parental allele, are
functionally haploid in the organism. Deletion or mutation of the single expressed allele
leaves an organism null for the imprinted gene. Several human neurogenetic disorders
arise from the disruption of the expressed alleles of imprinted genes. Prader-Willi and
Angelman syndromes are caused by the loss of function from paternally and maternally
inherited alleles of the chromosome 15q11-13 region, respectively (5). BechwithWiedemann syndrome is caused by the loss of function from maternal chromosome
11q15 (6). Silver-Russell syndrome is caused by disruption of imprinted genes on
chromosomes 7 (7) and 11 (6). Pseudohypoparathyroidism (Albright’s hereditary
osteodystrophy) and uniparental disomy 14 are also disorders caused by disruption of
imprinted genes (8). Complex genetic regulation underlies the imprinted genes in each
of these disorders, making it difficult to generate cell culture or animal models.
Human induced pluripotent stem cells (iPSCs) are becoming an attractive
approach to modeling complex genetic disorders, such as those involving genomic
imprinting (9). The use of somatic cells derived from patients enables the genetic
complexities to be captured in indefinitely self-renewing stem cells that are capable of
differentiation into virtually any lineage. Using iPSC technology, copy number variation
and uniparental disomy that often lead to disorders involving genomic imprinting can be
recapitulated in stem cells. Our group has generated iPSCs from individuals with
Prader-Willi syndrome, Angelman Syndrome, and Dup15q syndrome, which all involve
copy number variation at an imprinted locus (10–12). Epigenetic modifications are often
erased and established during the reprogramming process involved in the establishment
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of iPSC lines. Extensive analysis of the relevant epigenetic modifications and gene
expression is a stringent requirement for modeling disorders that involve genomic
imprinting to ensure appropriate expression of imprinted genes.

Imprinting disorders at chromosome 15q11-13
The chromosome 15q11-13 contains genes that are essential for human brain
development (5). Subregion of chromosome 15q11-13 is subject to genomic imprinting,
an epigenetic phenomenon in which genes are expressed in a parent-of-origin manner.
As a result, some of the genes in the region are expressed in a mono-allelic fashion.
When the active gene is absent, there is no compensation from the inactive counterpart.
Angelman Syndrome (AS) and Prader-Willi Syndrome (PWS) are two imprinting
disorders associated with this region. More than 70% of these two disorders are caused
by single allele deletion of the region (13). AS is caused by deletion of the maternallyinherited allele. PWS is caused by deletion of the paternally-inherited allele. The
deletion usually takes place during meiosis mediated by repetitive sequences. There
are 5 break points (BP1-BP5) in this region that are prone to be misaligned due to their
sequence repetitiveness. The majority of AS and PWS cases is between BP2-BP3
deletion, roughly 5 Mb. The estimated prevalence of these two disorders is at the rate
of 1 in 15,000 to 1 in 20,000 live births (13). While progresses have been made to
discover potential therapies, there is still no cure for these disorders at the moment.

Imprinting at chromosome 15q11-13
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Chromosome 15q11-13 displays two types of genomic imprinting. The first type
of imprinting is controlled by DNA methylation at the differentially methylated region
(DMR). Methylation occurs at the cytosine (C) on CpG islands. The methylation status
is usually reset during gametogenesis (14, 15). Once the methylation is set up, the
effect is global. The expression from all the tissues will behave in a parent-of-origin
specific manner. The DMR in chromosome 15q11-13 is at the promoter of
SNURF/SNRPN (16). This is called Prader-Will Syndrome imprinting center (PWS-IC).
The methylation only takes place on the maternal allele. Due to the DNA methylation,
many of the genes at the maternal allele are silenced. The paternal PWS-IC is not
methylated, leaving the paternal allele the only source of the RNAs and proteins in all
tissues. A map of the region is shown in Figure 1.
The second type of imprinting is controlled by long non-coding RNA (lncRNA). In
contrast to the imprinting caused by DNA methylation at DMRs, which has the global
effect in all tissues, this type of imprinting is tissue-specific. Schematic illustrations are
shown in Figure 2. The promoter of SNURF/SNRPN gives rise to a lncRNA that hosts a
protein coding RNA various small RNAs. The transcription pattern of the lncRNA can
be divided to two groups (proximal and distal). The proximal cluster includes
SNURF/SNRPN, SNORD107, SNORD64, SNORD108, SNORD109A, SNORD116, and
IPW. This transcript is expressed in all tissues. The distal cluster includes SNORD115,
SNORD109B, and UBE3A-ATS. This transcript is expressed in excessive amount in
neurons. UBE3A-ATS is a reciprocal transcript of a protein-coding gene UBE3A, and it

	
  

5	
  

is known that UBE3A-ATS is essential to silence UBE3A only in the brain (17). Due to
the tissue-specific expression of UBE3A-ATS, UBE3A is only silenced in the brain (18).

Angelman Syndrome and Prader-Willi Syndrome
AS was first described by Harry Angelman in 1965 (19). It is a relative rare
genetic disorder. Several population-based studies have reported the estimated
prevalence of AS to be around 1/10,000 to 1/20,000 (20–22). Symptoms of AS
individuals include severe intellectual disability, developmental delay, and speech
impairment so they are solely dependent on extra care from the family. The etiology of
AS is known to be disruption of the maternal UBE3A (23, 24). It is a single gene
disorder. Deletion of a 5-7 Mb maternally-inherited region containing UBE3A accounts
for most of AS cases (~70%). Mutation of the maternal UBE3A accounts for 20% of AS
cases. Imprinting defect at the PWS-IC and uniparental disomy together accounts for
7% of AS cases (13). While UBE3A expression is bi-allelic in other tissues, the
maternal copy is the only actively transcribed allele in the brain (18, 25). The paternal
copy is silenced by the reciprocal UBE3A-ATS in the brain (17). Targeting the UBE3AATS to unsilence the paternal UBE3A showed promises as a cure for AS since these
individuals still have the paternal copy present (26, 27). Other therapeutic approaches
have been focused on the function of UBE3A. UBE3A encodes an E3 ubiquitin ligase
that targets specific proteins for degradation through ubiquitin-proteasome system (28,
29). The function of UBE3A in the brain is still poorly understood. Although studies
have identified many UBE3A substrates, the findings only partially contributed to AS
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pathology, perhaps due to irrelevant cell type chosen (30–37). Even when a proper
model system was used (38, 39), a target of UBE3A that contributes to AS pathology
remains inconclusive (40).
PWS was first described by Andrea Prader, Heinrich Willi, and Alexis Labhart in
1956. PWS is another genetic disorder with the similar prevalence around 1/10,000 to
1/20,000 (13). PWS is characterized with cognitive impairment, poor muscle tone,
incomplete sexual development, obsessive eating behavior, and obesity (41). Unlike
AS, PWS is a contiguous gene disorder. 70% of PWS cases is due to 5-7 Mb deletion
of the paternal allele. 25% of cases is caused by uniparental disomy, and 5% of cases
is attributed to imprinting defect (13). Since PWS is not a single gene disorder, no
mutation cases have been identified. Previously, the cause of PWS is thought to be due
to loss of all paternally expressed genes. Recent studies reported cases of PWS with
atypical microdeletions (42–45). The minimal overlapping region that includes
SNORD116 cluster carrying multiple C/D box snoRNAs is likely to be the cause for
PWS. Although SNORD116 snoRNAs have potential gene targets due to the sequence
complementarity (46), their real function remains poorly understood. Similar to AS, the
inactive maternal copy is intact in the individuals with PWS. Reactivating the dormant
imprinted SNORD116 cluster has the potential to be a therapy for PWS. One study
demonstrated that disruption of a complex that deposits H3K9 trimethylation (H3K9me3)
on the maternal allele resulted in reactivation of SNORD116 (47).

iPSCs for disease modeling
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Genetically-manipulated AS mouse strains have helped us to recapitulate many
phenotypes of AS patients, to reveal potential problems in neuronal morphology and
synaptic plasticity of AS patients, and to monitor neuronal Ube3a imprinting during
neuronal development (48). They are, however, not ideal for studying mechanisms
underlying the regulation of neuron-specific UBE3A-ATS in human. Despite the fact
that Ube3a/UBE3A is imprinted by the same mechanism between mouse and human,
there is a subtle difference. In human, the long non-coding SNURF/SNRPN
transcription unit falls into two clusters, as mentioned earlier. The proximal cluster of
SNURF/SNRPN transcription unit is expressed ubiquitously in all tissues and
transcription stops at IPW. In mouse, however, the entire long non-coding
SNURF/SNRPN transcription unit is brain-specific and there is no tissue-specific
transcriptional stop at Ipw (49). Therefore, it is necessary to use human tissue as a
model system to study the underlying mechanism that governs the regulation of the
neuron-specific distal cluster of the SNURF/SNRPN transcription unit.
Taking advantage of the breakthrough discovery of human iPSCs in 2007 (50,
51), we generated AS patient-derived iPSCs and their neuronal derivatives with proper
characterizations (10). We also generated iPSCs from patients with PWS. With these
two iPSC lines and their neuronal derivatives, we are able to study transcription and
editing genomes in an allele-specific manner during neuronal development.
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UBE3A-ATS

Pat
Mat
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Figure 1. A map of chromosome 15q11-13 between break point (BP) 2 and 3.
Open circles are differentially methylated regions (DMRs) that are not methylated.
Close circles are methylated DMRs. Blue boxes denote genes exclusively expressed
from the paternal allele. Red box denotes the gene exclusively expressed from the
maternal allele. Grey boxes are genes expressed bi-allelically. Arrows indicate the
direction of transcription.
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Figure 2. Schematic illustrations of tissue-specific imprinting of UBE3A by
UBE3A-ATS. In non-neurons, the proximal portion of SNURF/SNRPN lncRNA
terminates at IPW. In neurons, the transcript does not stop at IPW. It transcribes
further and gives rise to the distal portion of SNURF/SNRPN lncRNA, which includes
UBE3A-ATS.

	
  

10	
  

2. Chapter 2
Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi
syndrome patient with an atypical deletion

Data presented in this chapter was published in the following paper

Title: Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi
syndrome patient with an atypical deletion
Authors: Kristen Martins-Taylor1#, Jack S. Hsiao1#, Pin-Fang Chen1, Heather GlattDeeley1, Adam J. de Smith2, 3, Alexandra I.F. Blakemore2, Marc Lalande1*, and Stormy
J. Chamberlain1*
1

Department of Genetics and Developmental Biology, University of Connecticut Health
Center, Farmington, CT, USA.
2

Section of Genomic Medicine, Imperial College London, Hammersmith Hospital
Campus, Du Cane Road, London UK.
3

Present address: Department of Epidemiology and Biostatistics, UCSF School of
Medicine, San Francisco, CA, USA
# equal contributors

My contribution: Schematic illustrations of chromosome 15q11-13, RNA FISH,
manuscript writing
Permission to reuse the content was granted by Oxford University Press
License number: 3942561058197
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Abstract
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two
neurodevelopmental disorders most often caused by deletions of the same region of
paternally-inherited and maternally-inherited human chromosome 15q, respectively.
AS is a single gene disorder, caused by the loss of function of the ubiquitin ligase E3A
(UBE3A) gene, while PWS is still considered a contiguous gene disorder. Rare
individuals with PWS who carry atypical microdeletions on chromosome 15q have
narrowed the critical region for this disorder to a 108 kb region that includes the
SNORD116 snoRNA cluster and the Imprinted in Prader-Willi (IPW) non-coding RNA.
Here we report the derivation of induced pluripotent stem cells (iPSCs) from a PWS
patient with an atypical microdeletion that spans the PWS critical region. We show that
these iPSCs express brain-specific portions of the transcripts driven by the PWS
imprinting center, including the UBE3A antisense transcript (UBE3A-ATS).
Furthermore, UBE3A expression is imprinted in most of these iPSCs. These data
suggest that UBE3A imprinting in neurons only requires UBE3A-ATS expression, and
not other neuron-specific factors. These data also suggest that a boundary element
lying within the PWS critical region prevents UBE3A-ATS expression in non-neural
tissues.

Introduction
Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are
neurodevelopmental disorders that are most commonly caused by large deletions of
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human chromosome 15q11-q13 (52). Individuals with AS suffer from cognitive
impairment, absent speech, seizures, ataxic gait, and a happy demeanor, while
individuals with PWS initially present with hypotonia and failure-to-thrive (53). PWS
individuals then go through a phase of normal growth before progressing to a period of
above-normal weight gain, and finally, a period of intense food seeking behavior and
hyperphagia (54). PWS leads to morbid obesity without diet, exercise, and often growth
hormone intervention. Individuals with PWS also suffer mild cognitive impairment, short
stature, and behavioral issues including obsessive-compulsive disorder (41). While the
two disorders are very different from one another, they can result from exactly the same
deletion, but the deletion differs in its parent-of-origin. AS is caused by deletions of
maternal chromosome 15q11-q13 and PWS is caused by the same deletion that occurs
on the paternally inherited allele (52).
The parent-of-origin specific effects of chromosome 15q11-q13 deletions occur
due to the regulation of the locus by genomic imprinting. A map of this region is shown
in Figure 1. The imprinting control region is a differentially methylated region
encompassing the promoter and first exon of SNURF-SNRPN. It is methylated on the
paternal allele and unmethylated on the maternal allele (55, 56). Several genes are
expressed exclusively from the paternally-inherited allele, including MKRN3 (57),
MAGEL2 (58), NDN (59), NPAP1 (60), SNURF-SNRPN (61, 62), SNORD107 (63),
SNORD64 (49), SNORD108 (63), SNORD109A (63), SNORD116 (49), IPW (64),
SNORD115 (49), SNORD109B (63), and UBE3A-ATS (17). Several paternally
expressed genes, including the SNORD genes, IPW, and UBE3A-ATS are non-coding
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RNAs (ncRNAs) driven from the SNURF-SNRPN promoter (63). In humans,
SNORD107, SNORD64, SNORD108, SNORD109A, SNORD116, and IPW are
expressed broadly across several tissues, but SNORD115, SNORD109B, and UBE3AATS are expressed exclusively in neurons, concomitant with the use of upstream exons
of the SNURF-SNRPN gene (10). Only one imprinted gene is expressed exclusively
from the maternally-inherited allele: UBE3A (18). This gene is expressed from both
parental alleles in most tissues, but is expressed exclusively from the maternallyinherited allele in neurons. The tissue-specific imprinted expression of UBE3A occurs to
due to the tissue-specific expression of UBE3A-ATS from the paternal allele (17, 10,
65). Mutations of UBE3A are sufficient to cause AS (66).
Recently, several individuals with PWS caused by rare, atypical smaller deletions
have been reported in the literature (42–44). Together these individuals have
delineated a smallest region of deletion overlap that underlies the PWS phenotype.
This smallest region of deletion overlap includes the SNORD116 cluster along with
other singleton snoRNAs and the ncRNA, IPW. Interestingly, lymphoblastoid lines from
two of these individuals were shown to express either SNORD115 or SNORD109B,
transcripts that are usually restricted to neurons (42, 43). We sought to determine
whether non-neural cells from one of these individuals expressed the neuron-specific
UBE3A-ATS and showed imprinted UBE3A expression. Here we report the derivation
and characterization of induced pluripotent stem cells from an individual with a small
atypical deletion spanning the SNORD116 cluster and IPW ncRNAs. We demonstrate
that iPSCs from this individual express UBE3A-ATS and show imprinted UBE3A
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expression, phenomena that are usually restricted to neurons. We show that this
occurs without the expression of the neuron-specific upstream exons of SNURFSNRPN, and results in a shortened SNURF-SNRPN/UBE3A-ATS ncRNA that is
resistant to silencing by the topoisomerase inhibitor, Topotecan. These data suggest
that the expression of UBE3A-ATS is sufficient for imprinted UBE3A expression and
that a boundary element lying within the smallest region of deletion overlap for the PWS
phenotype prevents the expression of UBE3A-ATS in non-neural tissues.

Materials and Methods
Cell Lines and Culture Conditions
AS del 1-0, PWS del 1-1, PWS del 1-7, and NML 1-0 iPSC lines used in this study were
cultured as described (10). Moreover, PWS small deletion (PWS SD) iPSC lines were
derived from patient fibroblasts (43) using the human polycistronic STEMCCA lentiviral
vector encoding OCT4, KLF4, SOX2, CMYC, and cultured following previously
published protocols (67). The iPSC lines were cultured in hESC medium, i.e.
Dulbecco’s modified Eagle’s medium/F-12 containing 20% KnockOut serum replacer,
0.1 mM nonessential amino acids, 1 mM L-glutamine (all from Life Technologies, Grand
Island, NY), 0.1 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO), supplemented
with 4 ng/ml bFGF (Millipore, Billerica, MA).

Immunocytochemistry:
Immunocytochemistry was performed as previously described (68), using rabbit anti-
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NANOG (Stemgent, Cambridge, MA), mouse anti-SSEA-4 (Developmental Studies
Hybridoma Bank, Iowa City, IA), mouse anti-TRA1-60 or mouse anti-TRA1-81 (Santa
Cruz Biotechnology, Santa Cruz, CA), or mouse anti-MAP2 (Millipore) antibodies. Cell
nuclei were counterstained with DAPI.

qRT-PCR
RNA was isolated from cells using RNA-Bee (Tel Test, Inc., Friendswood, TX), and
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit (Life
Technologies). Gene expression was analyzed using TaqMan® Gene Expression
Assays, and the GAPDH Endogenous Control TaqMan® Assay was used as an
endogenous control. Experiments were performed in triplicate. The data was analyzed
using RQ2.1 software (Applied Biosystems), normalized to either NML 1-0 iPSCs or
NML 1-0 10-week neurons. The Sybr qRT-PCR primers used to examine the
expression of SNRPN upstream U2 and U4 exons, relative to the GAPDH endogenous
control, are listed in Supplementary Table 2.

Methylation-Sensitive Restriction Endonuclease Quantitative PCR Assay
These assays were performed as described (10). The Methyl Profiler enzyme kit and
SNRPN primer set (Qiagen) were used according to the manufacturer’s instructions to
assay methylation at the PWS-IC. Percent methylation was reported plus or minus the
SD of three replicates. No intermediate methylation was observed in any of the
fibroblast or iPSC lines with this assay. The SNRPN primer set assays seven different
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CpG sites within the PWS-IC.

RT-PCR for UBE3A-ATS
To examine if the UBE3A-ATS was expressed in the PWS SD iPSC lines, conventional
PCR primers were used. RT-19 primers described in Runte et al. (63) were used to
analyze the expression of the UBE3A-ATS, and GAPDH was used as a loading control.
NML 1-0 10-week neurons were used as a positive control, since the UBE3A-ATS is
exclusively expressed in neurons.

Allele-specific RT-PCR
RNA was extracted from iPSCs using RNA-Bee (Tel Test, Inc.), followed by DNase
treatment using TURBO DNA-free Kit (Life Technologies AM1907). 1 μg of DNasetreated RNA was reverse transcribed using Superscript III (Life Technologies) at 53 °C
with strand-specific primers with tag sequences
(GGAAACAGCTATGACCATAACAATTTTCCCATTCAGAT for sense, and
CAGTCGGGCGTCATCATTTTCGTTATTGTTCCTTAGAA for anti-sense; tag
sequences are shown in bold). PCR was performed with annealing temperature at
60°C for 27 cycles using Advantage 2 Polymerase Mix (Clonetech, Mountain View, CA)
with primer sequences as the following: CATGAGCTTAGACTTCACCTTTCA and
GGGACCTCATGATGGCAATA. PCR products were run on precast Novex TBE 6%
polyacrylamide gel (Life Technologies) and post-stained with SYBR Gold (Life
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Technologies). Images were taken using LAS-3000 and the bands were quantified
using Multigauge V3.0 software (Fujifilm, Tokyo, Japan).

RNA FISH
iPSCs were grown on MEF-covered 12mm coverslips for 4-6 days. Prior to 4%
paraformaldehyde/PBS fixation for 10 minutes, coverslips were treated with CSK buffer
for 30 seconds, 1% Triton-X100/CSK buffer for 10 minutes, and CSK buffer for 30
seconds. Coverslips were then dehydrated with 70%, 85%, 95%, and 100% EtOH for 2
minutes each and air-dried before hybridizing with probes. SNORD115 probes were
made by labeling BAC RP11-37A4 using ENZO Nick Translation DNA Labeling System
(Enzo, Farmingdale, NY) with Alexa Fluor 594 dUTPs (Life Technologies) according to
the manufacturer’s instructions. UBE3A sense riboprobes were made from C7-3 cDNA
(69) cloned in pBluescript SK+ and in vitro transcribed using the MAXIscript T7/T3 Kit
(Life Technologies) with Alexa Fluor 488 UTPs (Life Technologies) according to the
manufacturer’s instructions. 1 μg of the transcribed riboprobes were hydrolyzed in
carbonate buffer (60 mM Na2CO3 and 40 mM NaHCO3) at 60 °C for 30 minutes and
neutralized in 1/20 volume of 10% acetic acid prior to purifying labeled riboprobes by
Micro Bio-Spin P-30 Tris column (Bio-Rad, Hercules, CA). 100 ng of labeled
SNORD115 was added to the UBE3A purified riboprobes along with 5 μg of human Cot1 DNA, 5 μg of salmon sperm DNA, and 2.5 volumes of 100% EtOH. Probes were
precipitated at -20 °C for 30 minutes and centrifuged at 12,000 rpm for 30 minutes.
Probe pellets were air-dried in the dark for 15 minutes and reconstituted in 100%
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formamide before heat denaturing at 85 °C for 10 minutes. 2 X hybridization buffer (4 X
SSC, 20% dextran sulfate, 2 mg/mL BSA) was added to the probes and applied equally
to coverslips for overnight hybridization at 37 °C in a dark humid chamber containing 2
X SSC/50% formamide. Coverslips were washed 3 times with 2 X SSC/50%
formamide, 3 times with 2 X SSC, and 3 times with 1 X SSC for 7 minutes each at 39 °C
prior to mounting with DAPI (Vectashield, Burlingame, CA). Images were taken using
Zeiss 780 confocal microscrope.

Neural differentiation
10 wk neurons were differentiated from iPSCs using the monolayer protocol as
described (70). Briefly, one-day post-split iPSCs were growing in N2B27 medium
supplemented with 500 ng/mL Noggin (R&D Systems, Minneapolis, MN) for 10 days.
These colonies were then spilt onto poly-L-lysine and laminin-coated plates using
StemPro EZ Passage tool (Life Technologies) and kept in N2B27 medium for 7 days.
Once rosettes were forming in these colonies, the cells were trypsinized and replated
onto poly-L-lysine and laminin-coated plates at higher density in N2B27 medium
supplemented with ROCK inhibitor overnight. The cells were kept in N2B27 medium for
another 6 days and split onto poly-L-lysine and laminin-coated plates with 1:4 to 1:6
ratio in neural differentiation media for 2 wks. The cells were then split with 1:6 ratio for
another 5 wks in neural differentiation media before topoisomerase inhibitor treatment.

Topoisomerase inhibitor treatment
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Topoisomerase inhibitor, topotecan (Molcan Corporation, Toronto, Ontario, Canada),
was dissolved in DMSO (Sigma-Aldrich) to make a 100 mM stock. A series of dilutions
was made to achieve the final concentrations of 100 μM, 10 μM, 1 μM, 100 nM, and 10
nM containing 0.1% DMSO for dose response curve experiments. The cells were
treated with various concentrations of topoisomerase inhibitor for continuous 6 days
prior to collecting RNA for experiments.

Results
Derivation of iPSCs from PWS small deletion patient
We obtained PWS patient fibroblasts with a 187 kb microdeletion of paternal
15q11-q13 (43), and reprogrammed them into iPSCs using the human polycistronic
STEMCCA lentiviral vector encoding OCT4, KLF4, SOX2, CMYC (67). The boundaries
of this deletion are diagrammed in Figure 1. Reprogrammed colonies were initially
identified morphologically and were subsequently validated using immunocytochemistry
to verify the expression of the pluripotency markers NANOG, SSEA-4, TRA1-60, and
TRA1-81 by immunocytochemistry (Figure 2A). PWS SD iPSCs had normal karyotypes
of 46 XY (Supplementary Figure 1), because the microdeletion cannot be detected by
G-banded karyotyping. We confirmed the deletion by quantitative RT-PCR for gene
expression analysis in PWS SD iPSCs for genes within the microdeletion, as described
in de Smith et al (43). Expression of SNORD116 and IPW was undetectable in the
PWS SD iPSCs, compared to the normal iPSC line NML 1-0, while genes located
outside of the deleted region (NDN, ATP10A, and GABRB3) were expressed in PWS
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SD iPSCs (Figure 2B). IPSC lines derived from a PWS patient harboring a large
deletion of paternal 15q11-q13 (PWS del 1-7), as well as from an AS patient with a large
deletion of maternal 15q11-q13 (AS del 1-0), were used as controls (10). The
boundaries of these deletions are also shown in Figure 1. PWS del 1-7 iPSCs did not
express the paternally expressed genes NDN, SNORD116 and IPW as expected, but
expressed ATP10A and GABRB3, while AS del 1-0 iPSCs expressed SNORD116 and
IPW, as well as NDN, ATP10A and GABRB3 (Figure 2B). To determine if the
differential methylation that marks the PWS-IC was maintained during reprogramming,
the methylation imprint of the PWS-IC was assessed in PWS SD fibroblasts and iPSCs
by methylation-sensitive restriction endonuclease quantitative PCR. Only an
unmethylated paternal allele was observed in AS del 1-0 iPSCs, while only a methylated
maternal allele was observed in PWS del 1-7 iPSCs, as previously described (10). Both
a methylated maternal allele and an unmethylated paternal allele were present in all of
the PWS SD fibroblasts and iPSC lines (Figure 2C), with percent methylation ranging
from 42 to 50% in most iPSC lines. The PWS SD 2-1 iPSC line appeared to have
aberrant methylation of the PWS-IC, and was excluded from further study. The
remaining PWS SD iPSC lines had methylation levels approximately equal to the PWS
SD fibroblast line. To confirm that the PWS SD iPSC lines were capable of multilineage differentiation, the cells were differentiated into embryoid bodies (EBs). After 16
days of spontaneous differentiation, the EBs were collected and analyzed by qRT-PCR
for lineage markers for all three germ layers, using a custom-designed TaqMan®
scorecard that incorporated lineage markers described in Bock et al (71). AS del 1-0,
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PWS del 1-7, and NML 1-0 iPSCs were used as positive controls in these assays. Early
lineage markers representing each of the three embryonic germ layers were expressed
in the EBs derived from each of the PWS SD iPSCs (Supplementary Figure 2),
demonstrating that they are capable of multi-lineage differentiation.

Paternal UBE3A is imprinted in non-neuronal cells
Two recent studies reported the expression of either SNORD115 or
SNORD109B, transcripts that are normally restricted to neurons, in PWS SD patient
lymphocytes (42, 43). To determine whether the neuron-specific gene was also
expressed in PWS SD iPSCs, we performed qRT-PCR for SNORD115. In agreement
with the expression data from lymphocytes, robust expression of SNORD115 was
observed in PWS SD iPSCs (Figure 3A). We then performed conventional RT-PCR for
UBE3A-ATS to determine whether this transcript extended into the UBE3A gene.
Strong expression of UBE3A-ATS was observed using primers anchored in exons
exclusive to UBE3A-ATS (Figure 3B). Since UBE3A-ATS was expressed, we
hypothesized that UBE3A expression would be imprinted; the expression of paternal
UBE3A-ATS in neurons represses paternal UBE3A expression (17, 10, 65). We first
tested this hypothesis using qRT-PCR to determine UBE3A mRNA levels in PWS SD
iPSCs. Normal iPSCs have twice as much UBE3A mRNA, as compared to AS and
PWS iPSCs with large deletions of chromosome 15q11-q13 (Figure 3C). This most
likely occurs because UBE3A expression is bi-allelic in iPSCs. Normal iPSCs have two
copies of UBE3A, while AS and PWS iPSCs harbor a large deletion of chromosome
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15q11-q13 with only a single copy of UBE3A. Although PWS SD iPSCs have two intact
copies of UBE3A, its relative expression is half of the normal iPSCs and similar to both
AS and PWS iPSCs, where there is only one copy of UBE3A (Figure 3C). This
suggests that UBE3A may be imprinted in the PWS SD iPSCs.
In order to determine whether one copy of UBE3A is repressed, we performed
allele-specific RT-PCR analysis of UBE3A expression. We first screened most of the
UBE3A cDNA to identify allele-specific polymorphisms. Upon finding no polymorphisms
in the cDNA, we then scanned the introns in the hopes that a polymorphism in the premRNA could be used to determine allele-specific expression. We identified a
polymorphism in intron 9 of UBE3A where one allele has 5 copies of a 26 nucleotide
repeat and the other allele has 4 copies of this repeat in PWS SD iPSCs. The normal
iPSC line is also polymorphic at this site, with different numbers of repeats. We
performed semi-quantitative strand-specific RT-PCR using primers flanking this
polymorphism to determine the allele-specific expression of UBE3A sense pre-mRNA
transcripts. As expected, the UBE3A sense is transcribed equally from both alleles in
the normal iPSC line. In PWS SD iPSCs, however, most of the UBE3A sense transcript
comes from only a single allele, presumably due to the aberrant expression of UBE3AATS from the paternal allele in these iPSCs (Figure 3D).
To further confirm that the paternally inherited allele of UBE3A is silenced and
the maternally inherited allele is expressed in PWS SD iPSCs, we performed RNA FISH
using a riboprobe that specifically detects UBE3A sense transcripts and a BAC probe
that detects SNORD115 transcripts. In normal iPSCs, UBE3A is actively transcribed
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from both alleles, and SNORD115 transcripts are not detected, as expected (Figure 3E,
left panel). In PWS SD iPSCs, most of the cells have a single expressed copy of
UBE3A that does not co-localize with the single expressed copy of SNORD115,
demonstrating that paternal UBE3A is repressed, presumably by the expression of
UBE3A-ATS (Figure 3E, middle and right panels). Notably, a small portion of cells (17%
+ 2%) still express UBE3A from both parental alleles even though they produce
SNORD115, indicated by the asterisk (Figure 3E, right panel).

SNRPN upstream exon usage is not affected in PWS SD iPSCs and neurons
In brain, expression of UBE3A-ATS and imprinted UBE3A expression occurs
concomitantly with the use of several upstream exons of SNURF-SNRPN, diagrammed
in Figure 4A. Use of these upstream exons is thought to shift expression from the
protein coding exons of SNURF-SNRPN to the non-coding downstream exons (72). In
humans, at least one upstream SNURF-SNRPN exon is used in many non-neural
tissues. Coincidently, downstream ncRNAs between and SNURF-SNRPN and IPW
(inclusive of IPW) are expressed in many tissues, including iPSCs. To determine
whether the aberrant expression of UBE3A-ATS correlated with the use of the neuronspecific upstream exons of SNURF-SNRPN, we differentiated the PWS SD iPSCs into
neurons to compare upstream exon usage between neural and non-neural tissue.
In order to choose PWS SD iPSC lines that are capable of efficient differentiation
into neurons, we examined the expression levels of genes critical for specification into
the neural lineage in d16 EBs (Supplementary Figure 3A), using the scorecard
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described above. In addition to the lineage markers used to verify multi-lineage
differentiation potential, this card also had probe-primer sets for an abbreviated list of
widely used neural lineage marker genes (Supplementary Table 1) (71). Probe-primer
sets to the pluripotency genes NANOG and ZFP42/REX1 were also included in the
scorecard to determine whether pluripotency genes were appropriately turned off during
differentiation (Supplementary Figure 3B). We used AS del 1-0 as a calibrator sample
for these assays, since this AS iPSC line differentiates robustly into neurons using
conventional neural differentiation assays (10). The PWS del 1-1 iPSC line was used
as a negative control for these assays, since it does not robustly differentiate into
neurons. Differentiation propensity of the PWS SD iPSC lines into neurons was
determined based two criteria: 1.) robust expression of neural lineage markers, and 2.)
silencing of the pluripotency genes. PWS SD 2-8 and PWS SD 2-9 iPSC lines were
found to have the highest propensities to differentiate into neurons, due to the robust
expression of neural lineage markers and silencing of the pluripotency genes. Despite
the robust expression of the neural lineage markers in the PWS SD 2-4 iPSC line, this
line may have limited differentiation potential in conventional neural differentiation
assays due to the inappropriate expression of the pluripotency genes in d16 EBs. PWS
SD 2-8 and PWS 2-9 iPSC lines were chosen for further analysis.
Both PWS SD 2-8 and PWS SD 2-9 iPSC lines were differentiated into neurons,
as previously described (10). Following 10 weeks of differentiation, MAP2-positive
neurons were identified by immunocytochemistry. A representative image is shown for
10-week PWS SD 2-8 iPSC-derived neurons (Figure 4B). The expression of the
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neuron-specific upstream U1A, U2, and U4 exons was compared between PWS SD
iPSCs and PWS SD iPSC-derived neurons by quantitative RT-PCR (Figure 4C). The
U1A and U2 exons were almost exclusively expressed in the neuron samples and were
nearly undetectable in all six iPSC lines. Exon U4, which showed robust expression in
NML 1-0, PWS SD 2-8, and PWS SD 2-9 iPSC-derived neurons, was expressed at low
levels in NML 1-0 and AS del 1-0 iPSCs, was barely detectable in PWS SD iPSCs, and
was undetectable in PWS del 1-7 iPSCs. Thus, imprinted expression of UBE3A in PWS
SD iPSCs was not caused by the aberrant expression of the neuron-specific upstream
SNRPN exons. Moreover, these results suggest that expression of UBE3A-ATS is
sufficient for imprinted expression of UBE3A and that additional neuron-specific events
were not required for this imprinting in non-neural tissues.

The shortened UBE3A-ATS in PWS SD neurons is less amenable to silencing by
Topotecan
Topoisomerase inhibitors have been shown to repress Ube3a-ats in mouse (26).
This effect is length-dependent and is shared between mouse and human across the
genome, with longer genes showing greater repression by topoisomerase inhibitors
(73). Since the UBE3A-ATS transcript is reduced by 187 kb in PWS SD iPSCs, we
sought to determine whether a topoisomerase inhibitor was less effective on the
shortened UBE3A-ATS transcript. We treated 10-week old AS and PWS SD iPSCderived neurons with increasing doses of Topotecan, a campothecin-type
topoisomerase inhibitor that was previously shown to be effective at reducing mouse
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Ube3a-ats. We then performed qRT-PCR using a probe-primer set that recognizes the
SNURF-SNRPN ncRNA in the region of SNORD115. This SNORD115 host transcript
can be used as a proxy for UBE3A-ATS, and thus avoids possible confusion with the
sense UBE3A transcript. Topotecan was highly effective in reducing the SNURFSNRPN ncRNA (which includes UBE3A-ATS) in AS iPSC-derived neurons, showing
90% reduction of the transcript at a 10 μM dose (Figure 5). However, topotecan was
less effective in repressing the shortened SNURF-SNRPN ncRNA in PWS SD neurons,
only showing a maximum 46% reduction compared to the 90% reduction seen in AS
neurons (Figure 5).

Discussion
Here we show that iPSCs derived from patients with PWS due to a small deletion
on paternal chromosome 15q11-q13 express UBE3A-ATS and have imprinted
expression of UBE3A. UBE3A-ATS expression is typically restricted to neurons, and
consequently so is UBE3A imprinting. Work over the past decade has steadily focused
on UBE3A-ATS as the mediator of UBE3A imprinted expression (17, 10, 65, 74). Thus,
understanding the neuron-specific regulation of UBE3A-ATS is critical for understanding
the regulation of UBE3A imprinted expression.
UBE3A-ATS is within the neuron-specific portion of the SNURF-SNRPN ncRNA,
which also includes SNORD115 and SNORD109B (63). In non-neuronal tissues and
cell types, transcription of the SNURF-SNRPN locus usually stops at IPW, and thus
SNORD115, SNORD109B, and UBE3A-ATS are not expressed (10). In contrast to
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normal iPSCs where the neuron-specific portion of SNURF-SNRPN is not expressed,
PWS SD iPSCs showed robust expression of SNORD115 and UBE3A-ATS (Figures 3A
and 3B). In normal iPSCs, the polyadenylation sites that lie at the 3’ end of IPW are
likely transcriptional stops for the SNURF-SNRPN transcript. These sites, as well as
additional as-of-yet unidentified regulatory elements, have been removed in the PWS
SD patient derived iPSCs, placing the SNURF-SNRPN promoter and exon 1 in direct
association with the SNORD115 portion of the transcript. The identification of the
regulatory elements that stop SNURF-SNRPN transcription will be an important clue in
understanding the neuron-specific regulation of UBE3A-ATS and imprinted UBE3A
expression. Alternatively, the SNURF-SNRPN transcript is terminated at IPW because
that is the maximum length that can be transcribed during the iPSC cell cycle.
The aberrant expression of UBE3A-ATS transcript in PWS SD iPSCs leads to
imprinted UBE3A expression (Figure 3). We demonstrated this in three ways. First, we
determined UBE3A expression levels. UBE3A mRNA levels in PWS SD iPSCs are
consistent with having only a single expressed allele of the gene, like PWS and AS
iPSCs harboring large deletions of paternal and maternal chromosome 15q11-q13,
respectively. Normal iPSCs have UBE3A mRNA levels consistent with having two
expressed copies of the gene (Figure 3C). Secondly, we determined whether UBE3A is
expressed from one or two alleles in PWS SD iPSCs using strand-specific RT-PCR.
UBE3A is primarily expressed from a single allele in these cells, and UBE3A-ATS is
expressed exclusively from the opposite allele (Figure 3D). Finally, we used RNA FISH
to confirm that UBE3A was coming from a single allele that did not produce the
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SNORD115 transcript (Figure 3E). These data suggest that UBE3A-ATS expression is
sufficient for the imprinted expression of UBE3A, and that additional neuron-specific
factors are not necessary for the repression of paternal UBE3A.
Interestingly, imprinting of UBE3A is not complete in every cell, as evidenced by
both the RT-PCR and RNA FISH data. In fact, the RNA FISH data demonstrated that
approximately 20% of the cells showed juxtaposed UBE3A and SNORD115 expression
in the same cell (Figure 3E). While we do not know the exact reason for this, we
speculate that in the dividing PWS SD iPSCs, replication may cause the premature
termination of the SNURF-SNRPN/SNORD115 transcript prior to overlapping UBE3A,
thus allowing UBE3A transcription in the sense direction. Indeed, paternal Ube3a has
been shown to retain active histone modifications, even in brain (75). The PWS SD
iPSCs described here show that imprinted UBE3A expression can be maintained by the
UBE3A-ATS, even in the presence of a transcriptionally-competent paternal UBE3A
promoter. It is therefore not necessary that paternal UBE3A undergoes repressive
chromatin changes, even in neurons where it is normally imprinted.
There was a slight discrepancy between the FISH and RT-PCR data. The FISH
data showed that 17%+/-2% of cells showed detectable expression from the paternal
allele of UBE3A (Figure 3E, lower panel), while the RT-PCR data showed that 27% of
the total UBE3A RNA came from the paternal allele (Figure 3D). There are at least
three possible explanations for this: 1.) the FISH assay failed to detect UBE3A in some
cells where it was expressed from the paternal allele at a level lower than the detection
limit; 2.) the active paternal allele is expressing more UBE3A than the maternal allele in
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some or all of the cells, so that ~17% of the cells are producing ~27% of the RNA; or 3.)
the semi-quantitative RT-PCR experiment may suffer from amplification bias or
measurement bias (i.e. the genomic DNA in PWS SD 2-8 was measured as 54%
paternal and 46% maternal).
Topoisomerase inhibitors were shown to reactivate the paternal allele of Ube3a
in mouse neurons by repressing Snurf-Snrpn/Ube3a-ats (26). This occurs because
topoisomerases are required for efficient transcription of long genes in both human and
mouse neurons (73). The 187 kb deletion of the SNORD116 cluster enabled us to
examine the effect of a topoisomerase inhibitor, topotecan, on a shortened SNURFSNRPN/UBE3A-ATS transcript. We found that topotecan was not as effective on the
shortened UBE3A-ATS transcript as it was on the full-length transcript, further
supporting the observation that topoisomerases are important for the transcription of
UBE3A-ATS and other long genes (Figure 5).
Altogether, these data demonstrate that the SNURF-SNRPN transcript is
regulated by a boundary element in non-neurons, and that in its absence, the
expression of UBE3A-ATS is sufficient to cause UBE3A imprinted expression in the
absence of additional neural factors. We do not know what comprises this boundary
element, but we speculate that either the polyadenylation sites in the IPW gene act as
transcriptional terminators, that CTCF protein binding sites downstream of IPW separate
active versus inactive chromatin territories, or a combination of those two possibilities
work to perform the boundary function. These findings provide important clues as to the
regulation of the SNURF-SNRPN ncRNA in humans. Furthermore, they demonstrate
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that iPSCs derived from rare individuals with atypical deletions can teach us important
lessons about the mechanisms of gene regulation.
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Figure 1. Map of chromosome 15q11-q13 region. Map of chromosome 15q11-q13
between common break points 2 and 3 (BP2 and BP3). Blue dotted lines represent the
regions deleted on the paternal allele, and red dotted line represents the regions deleted
on the maternal allele for the indicated cell lines. Blue and red boxes denote genes
expressed exclusively from paternal and maternal alleles, respectively. Grey boxes
denote genes expressed biallelically. Differential methylated regions (DMRs) are shown
using circles where open and closed circles represent unmethylated and methylated
alleles, respectively. Arrows indicate the direction of transcription. A solid blue line
represents paternal SNURF/SNRPN transcripts expressed in most cell types, whereas
a dashed blue line indicates neuron-specific transcripts, including UBE3A-ATS.
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Figure 2. Characterization of PWS SD iPSC lines. A.) Immunocytochemistry for the

	
  

33	
  

pluripotency markers NANOG, SSEA-4, TRA1-80, and TRA1-81. Cell nuclei were
counterstained with DAPI. Scale bar = 100 μm. B.) Expression of genes within 15q11q13 region iPSCs to confirm deletion in PWS SD iPSCs. GAPDH was used as en
endogenous control, and data was normalized to NML 1-0 iPSCs. C.) Methylation
analysis of PWS-IC within SNPRN, using a methylation-sensitive restriction
endonuclease quantitative PCR assay, confirming the maintenance of genomic
imprinting at the PWS-IC following reprogramming in PWS SD iPSCs. PWS del 1-7 and
AS del 1-0 iPSCs were used as controls. Percent methylation was reported plus or
minus the SD of three replicates.
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Figure 3. Imprinting of paternal UBE3A in non-neuronal cells. A.) Gene expression
analysis of SNORD115 snoRNAs in iPSCs by qRT-PCR. GAPDH was used as an
	
  

35	
  

endogenous control, and data was normalized to NML 1-0 10-week neurons. B.)
Analysis of UBE3A-ATS expression in PWS SD iPSCs. RT-19 primers were used to
analyze the expression of the UBE3A-ATS (63), and GAPDH was used as a control.
NML 1-0 10-week neurons were used as a positive control, since the UBE3A-ATS is
exclusively expressed in neurons. C.) Expression analysis of UBE3A in iPSCs.
GAPDH was used as an endogenous control, and data was normalized to NML 1-0
iPSCs. PWS del 1-7 and AS del 1-0 iPSCs were used as controls. D.) Allele-specific
RT-PCR showed equal expression of UBE3A in NML 1-0 iPSCs. In PWS SD iPSCs, the
paternal UBE3A is repressed while UBE3A-ATS is expressed (S=sense,
ATS=antisense, and GM=genomic DNA). E.) RNA FISH using a riboprobe that
specifically detects UBE3A sense transcripts (green) and a BAC probe that detects
SNORD115 transcripts (red). UBE3A is actively transcribed from both alleles, and
SNORD115 transcripts are not detected in NML 1-0 iPSCs. Scale bars = 5 μm. In
PWS SD iPSCs, 83% of SNORD115-positive nuclei showed monoallelic expression of
UBE3A and 17% of that showed biallelic expression of UBE3A, as indicated by the
asterisk.
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Figure 4. SNRPN upstream exon usage in PWS SD iPSCs neurons. A.) Map
showing the organization of upstream SNURF-SNRPN exons (76). Upstream exons
U1B, U1B’, U1A, and U2 are largely neuron-specific, as indicated by the bracket. Exon
U4 is expressed at low levels in a variety of tissues, including iPSCs. It is unclear
whether U3 and U5 are brain-specific. The location of the PWS-IC is indicated by a
half-filled circle. B.) Immunocytochemistry for the neural marker MAP2 in PWS SD 2-8
10-week neurons. Cell nuclei were counterstained with DAPI. Scale bar = 100 μm. C.)
Expression analysis of upstream SNRPN exons. GAPDH was used as an endogenous
control, and data was normalized to NML 1-0 10-week neurons, since these exons are
predominately expressed in neurons.
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Figure 5. Topotecan is less effective in repressing the UBE3A-ATS in PWS SD
neurons. Relative expression of SNORD115 by qRT-PCR in 10 wk neurons derived
from PWS SD and AS iPSC lines treated with various concentrations of Topotecan.
GAPDH was used as an endogenous control. ** p-value < 0.05
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Supplementary methods
qRT-PCR: After 16 days of spontaneous differentiation, embryoid bodies (EBs)
representative of each iPSC line were collected, RNA was extracted using RNA-Bee
(Tel Test, Inc.), and cDNA was synthesized using High Capacity cDNA Reverse
Transcription Kit (Life Technologies). A custom designed TaqMan® Gene Signature
Array Card (Life Technologies) was developed to include lineage marker genes
representative of all three germ layers adapted from Bock et al (71) (Supplementary
Table 1). For lineage marker expression, CT values were normalized to those of 18S
rRNA using RQ manager software (Applied Biosystems), generating a ΔCT value for
each gene on the array, which indicates the relative expression levels. Expression
levels as a percentage of GAPDH were reported for each lineage marker gene, as
described (10).
To determine the neural differentiation propensities of each iPSC line, an
abbreviated list of neural lineage markers described in Bock et al (71), as well as
additional widely used neural lineage marker genes, were included in the custom
designed TaqMan® Gene Signature Array Card (Life Technologies; Supplementary
Table 1). The pluripotency genes NANOG and ZFP42/REX1 were also included in the
array card. D16 EBs were collected, and gene expression was analyzed as described
above. Data was normalized to AS del 1-0 d16 EBs and displayed as Log2 ratio.

Karyotype Analysis: Karyotype analysis was performed on PWS SD 2-8 and PWS SD 29 iPSC lines by the iPSC & Chromosome Core at the University of Connecticut Health
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Center on G-banded metaphase cells, using standard protocols for high resolution Gbanding. 20 metaphase cells were counted for each iPSC line.
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Supplementary Table 1. Taqman Assays printed on custom card
Gene
ITGAX
HHEX
LEF1
TNFRSF1A
ADIPOQ
T
KIT
SRF
INHBA
ANPEP
MME
ITGAL
FOXA2
CDX2
HNF1A
GATA6
GCG
NEUROG3
CD44
GATA4
PDX1
SLC2A2
NKX2-5
SST
NR2E1
SNAI2
APOE
SOX9
BMP2
ABCG2
FUT4
MCAM
FOXD3
NEFL
SOX4
THY1
TCF4
PAX3
NCAM1
CD34
SOX10

	
  

Taqman Assay ID
Hs01015070_m1
Hs00242160_m1
Hs01547250_m1
Hs01042313_m1
Hs00605917_m1
Hs00610080_m1
Hs00174029_m1
Hs00182371_m1
Hs01081598_m1
Hs00952642_m1
Hs00153510_m1
Hs00158218_m1
Hs00232764_m1
Hs01078080_m1
Hs00167041_m1
Hs00232018_m1
Hs01031536_m1
Hs01875204_s1
Hs01075861_m1
Hs00171403_m1
Hs00426216_m1
Hs01096904_m1
Hs00231763_m1
Hs00174949_m1
Hs01128417_m1
Hs00950344_m1
Hs00171168_m1
Hs00165814_m1
Hs00154192_m1
Hs01053790_m1
Hs01106466_s1
Hs00174838_m1
Hs00255287_s1
Hs00196245_m1
Hs00268388_s1
Hs00174816_m1
Hs00971331_m1
Hs00240950_m1
Hs00941821_m1
Hs00990732_m1
Hs00366918_m1

Gene
LMX1A
TWIST1
PAX6
NOTCH1
NES
ITGA6
NEUROG1
FGF2
EPHB4
OLIG2
MAP2
ICAM1
FAS
DLX5
FGFR3
MSI1
EOMES
CDH2
MAPT
ISL1
SYP
ITGAM
MNX1
TH
SOX1
DLL1
TBR1
PAX7
PAX2
CRABP2
NEUROG2
FOXG1
EMX1
GBX2
EN1
HOXB4
OTX2
NEUROD1
SOX2
KLF4
ZFP42
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Taqman Assay ID
Hs00602600_m1
Hs00361186_m1
Hs01088112_m1
Hs01062014_m1
Hs00707120_s1
Hs01041011_m1
Hs01029249_s1
Hs00266645_m1
Hs00174752_m1
Hs00377820_m1
Hs00258900_m1
Hs00164932_m1
Hs00531110_m1
Hs00193291_m1
Hs00179829_m1
Hs00159291_m1
Hs00172872_m1
Hs00983056_m1
Hs00902194_m1
Hs00158126_m1
Hs00300531_m1
Hs00355885_m1
Hs00907365_m1
Hs00165941_m1
Hs01057642_s1
Hs00194509_m1
Hs00232429_m1
Hs00242962_m1
Hs01057416_m1
Hs00275636_m1
Hs00702774_s1
Hs01850784_s1
Hs00417957_m1
Hs00230965_m1
Hs00154977_m1
Hs00256884_m1
Hs00222238_m1
Hs00159598_m1
Hs01053049_s1
Hs00358836_m1
Hs01938187_s1

ITGB1
ITGA4
TCF3
NOG
NGFR
CEACAM5
SDC1

	
  

Hs00559595_m1
Hs00168433_m1
Hs01012685_m1
Hs00271352_s1
Hs00609976_m1
Hs00944025_m1
Hs00896423_m1

NANOG
SHH
CAMK2A
CEACAM1
ACTB
GAPDH
18S
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Hs02387400_g1
Hs00179843_m1
Hs00392405_m1
Hs00236077_m1
Hs99999903_m1
Hs02758991_g1
Hs03003631_g1

Supplementary Figure 1. Cytogenetic analysis of PWS SD iPSCs. G-banded
karyotype analysis of PWS SD 2-8 iPSCs passage (p) 22, and PWS SD 2-9 iPSCs p22.
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Supplementary Figure 2. Multi-lineage differentiation capacity of PWS SD iPSCs.
Lineage marker analysis for expression of genes representing all three germ layers in
day 16 spontaneously differentiated EBs. CT values were normalized to 18S rRNA,
generating a ΔCT value for each gene on the array to indicate relative expression
levels. Expression levels are displayed as a percentage of GAPDH for each lineage
marker gene. AS del 1-0, PWS del 1-7, and NML 1-0 iPSCs were used as positive
controls.

	
  

45	
  

Supplementary Figure 3. Differentiation propensity of PWS SD iPSCs into
neurons. The iPSC lines were spontaneously differentiated into d16 EBs. 18S rRNA
was used as an endogenous control, and data was normalized to AS del 1-0 d16 EBs,
since this AS iPSC line differentiates robustly into neurons using conventional neural
differentiation assays. Data was displayed as Log 2. PWS del 1-1 iPSC line was used
as a negative control for these assays, since it does not robustly differentiate into
neurons. Differentiation criteria: 1.) robust expression of neural lineage markers, and 2.)
silencing of the pluripotency genes.
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A bipartite boundary element regulates tissue-specific imprinting of UBE3A
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Introduction
Angelman Syndrome (AS) is a neurodevelopmental disorder characterized by
developmental delay, speech impairment, ataxia, and severe intellectual disability (77–
79). It is caused by mutation (66, 80) or deletion (23, 24) of the maternally inherited
allele of UBE3A. The loss of maternally inherited UBE3A cannot be compensated from
the paternally inherited copy because it is imprinted in a tissue-specific manner in the
brain (18, 25). The imprinting is controlled by a reciprocal neuronal-specific UBE3AATS (UBE3A-ATS) transcript (17). This transcript is part of the >600 kb
SNURF/SNRPN long non-coding RNA (lncRNA) transcription unit initiated from the
paternal SNURF/SNRPN promoter (63). The maternal SNURF/SNRPN promoter,
however, is completely inactive due to methylation at the promoter (56, 81, 82). The
paternal SNURF/SNRPN lncRNA can be further divided into two clusters according to
their tissue-specific transcription patterns in human (10). The proximal cluster, which
includes protein-coding SNURF/SNRPN, non-coding small nucleolar RNA 116
(SNORD116), and non-coding IPW, is ubiquitously transcribed in all tissues. The distal
cluster, which includes non-coding small nucleolar RNA 115 (SNORD115), and noncoding UBE3A-ATS, is transcribed most abundantly in the brain, and barely detected in
other tissues (83).
We previously reported that the distal portion of SNURF/SNRPN lncRNA is
expressed in induced pluripotent stem cells (iPSCs) derived from an individual with an
atypical paternal deletion (12). This paternal deletion spans from SNURF/SNRPN intron
1 to downstream of PWAR1, an exon originally identified amongst SNRPN transcripts
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isolated from cultured cells (16). The deletion includes a region separating the
transcribed proximal portion of SNURF/SNRPN lncRNA from the non-transcribed distal
portion. In addition, at least one other individual with an atypical paternal deletion
including this region also showed expression of the distal portion of SNURF/SNRPN
lncRNA in a non-neuronal cell type, such as peripheral blood mononucleocytes (42).
These unique paternal deletions provided evidence that imprinting of UBE3A can occur
in non-neuronal tissues. Therefore, we hypothesized that the expression of distal
SNURF/SNRPN and UBE3A imprinted expression is controlled by the presence of a
chromatin boundary within this critical region. We speculated that polyadenylation
sequences at IPW and/or a cluster of CTCF binding at PWAR1 in this region
independently or collectively act as transcriptional terminators in non-neuronal cells
(12).
Here, we used CRISPR/Cas9 to remove IPW and PWAR1, revealing that these
two components collectively serve as a bipartite boundary to regulate the distal portion
of SNURF/SNRPN lncRNA. SNORD115 and UBE3A-ATS, two portions of the distal
SNURF/SNRPN lncRNA, were detected in iPSCs in which the putative boundary is
removed. We also provide evidence that these two elements are directional. Disruption
of the boundary causes irregular imprinting of UBE3A during neural differentiation
process. Deletion of the boundary leads to early imprinting of UBE3A whereas
inversion of it perturbs UBE3A imprinting in neurons. In addition, we showed that
directly attaching the SNURF/SNRPN promoter to the UBE3A-ATS portion of the
lncRNA causes complete imprinting of UBE3A in iPSCs.
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Materials and Methods
Cell Culture
AS iPSC (AS del 1-0) and PWS iPSC (PWS del 1-7) lines were generated and
maintained as previously described. Briefly, iPSCs were cultured in hESC medium with
the following components. Dulbecco’s modified Eagle’s medium/F-12, 20% Knock-Out
serum replacer, 0.1 mM non-essential amino acids, 1 mM L-glutamine, 0.1 mM bmercaptoethanol, and 4 ng/mL bFGF. Colonies were grown on MEF and split every
week.

ChIP qPCR
ChIP qPCR was performed using Millipore EZ-Magna ChIP G – Chromatin
Immunoprecipitation Kit (17-409) following manufacturer’s instructions. Briefly, 6-10
million cells were used for fixation. Sonication took place in 0.5 mL of nuclear lysis
buffer. 4 uL of ChIPAb+ CTCF (17-10044) antibody was added to a 50 uL of sonicated
DNA aliquot with 450 uL ChIP dilution buffer for immunoprecipitation overnight. The
washed immune-DNA complexes were reverse-crosslinked in 100 uL ChIP Elution
buffer. Instead of using provided column for DNA purification, the process was carried
out using phenol-chloroform. 200 uL of nucleases water and 200 uL of phenolchloroform were added to the 100 uL ChIP Elution buffer. After centrifugation, aqueous
phase was transferred to a new tube. 200 uL of chloroform was added for extra step of
purification. The aqueous phase was transferred to a new tube and the precipitation
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took place at -20 for 30 minutes after adding 1 mL of 100% ethanol, 4 ug of glycogen,
and 1/10 of total volume of 5M NaCl. After centrifugation, the DNA pellet was washed
with 75% ethanol. 50 uL of nuclease-free water was added to the DNA pellet after
ethanol evaporated. The DNA was further diluted in a 1:5 ratio for qPCR. 5 uL of
diluted DNA was added to a 20 uL reaction using SYBR green PCR master mix from
Thermo Fisher Scientific (4309155). qPCR primers are list in table 1.

ChIP-seq
ChIP material was obtained following the same process in ChIP qPCR. Library
preparation and sequencing run were performed at Yale sequencing core. Obtained
FASTQ files were mapped and analyzed using Homer with the parameters described
previously.

CRISPR and single-strand oligonucleotide (ssODN) design
CRISPR gRNA sequences were designed using CRISPR Genome Engineering
Resource (http://crispr.mit.edu) (84). The gRNA sequence was cloned in px459 V2
vector following the published protocol (85, 86). ssODN was designed following the
previously described protocol (87). The CRISPR sequences used in this paper are
listed in table 2.

Electroporation and clone-screening for genomic deletion
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6-10 million AS iPSCs were treated with ROCKi (Calbiochem; Y-27632) 24 hours prior
to electroporation. iPSC colonies were singlized with Accutase for 30 minutes. Cells
were resuspended in 800 uL of cold PBS and 10 ug of each CRISPR flanking the
desired deletion was added before electroporation using BioRad Gene Pulser Xcell with
the following conditions: 250 V, 500 uF, 0.4 cm cuvettes (88). In the case of loxP
insertion, 2 single stranded oligonucleotides were also added along with 2 CRIRPR
plasmids. Electroporated cells were transferred to a 15 conical tubes and centrifuged at
1000 rpm for 3 minutes to remove debris (89). Cells were then resuspended in hESC
media and seeded on DR4 MEFs supplemented with ROCKi for the first 24 hours after
electroporation. In the next 48 hours, 1 ug/ml puromycin was used to select cells
receiving the CRISPR plasmids. Medium was changed every 24 hours during this
period. After drug selection, regular hESC medium was changed everyday until
colonies were formed. Colonies were picked to screen for deletion with primers
designed as previously described. Primers were designed as described (90) and are
listed in Table 3 .

4C-seq
The following procedure of harvesting nuclei was described previously (91).
Approximately 2 million of iPSCs and iPSC-derived neurons were fixed in formaldehyde
(1% final) and quenched in glycine (150 mM final) at room temperature on a shaker for
10 and 5 minutes, respectively. Cells were harvested and centrifuged for 5 minutes at
2000 g at 4 C. Cell pellets were lyzed in 1 mL of cell lysis buffer containing proteinase
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inhibitor cocktail 3 (Calbiochem) on ice for 20 minutes prior to douncing with pestle A for
10 strokes and pestle B for 30 strokes. The nuclei were collected at 2000 g, 4C for 5
minutes, washed and resuspend in 500 uL of 1x restriction enzyme buffer (NEB
Cutsmart). The following 4C material preparation procedure was adapted from
previously described protocols (92). The nuclei in NEB cutsmart buffer was incubated
at 65 C for 10 minutes on a thermal mixer with 800 rpm after adding 15 uL of 10% SDS.
150 uL of 10% Triton X-100 was added and incubated at 37 for 10 minutes on a nutator.
200 units of Nla3 (NEB) and 16.5 uL 10x NEB cutsmart were added for the fist digestion
at 37 C overnight on a nutator. Additional 50 units of Nla3 for 2 hours were used to
ensure complete digestion. Nla3 were heat inactivated prior to spliting into 3 ligations
reaction. Each ligation solutions were prepared on ice with the following components:
220 uL heat inactivated digested material, 745 uL of 10X T4 Ligase buffer, 745 uL 10%
Triton X-100, 800 ug BSA, 5.5 mL nuclease-free water, and 2000 unit of NEB T4 DNA
ligase. Prepared ligation solutions were incubated at 15 C overnight. 15 uL of 20 mg/ml
proteinase K (NEB) was added to the ligation solution, and incubated at 65C overnight
to reverse crosslinking. Reverse-crosslinked 3C material was purified using phenolchloroform followed by chloroform prior to ethanol precipitation overnight. The 3C
library was pelleted, air-dried, and resuspended in 10 mM Tris-HCl (pH 8.0). The
second digestion was performed at 37 C overnight with components listed in the
followings: 445 uL of 3C library, 50 uL of 10X Dpn2 buffer, 150 units of Dpn2. After
digestion, Dpn2 was inactivated at 65 C for 25 minutes. The following components
were added to the heat-inactivated material for second ligation at 15 C for 4 hours: 1.4
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mL 10X T4 ligase buffer, 12.6 mL cold nuclease-free water, 6000 units of NEB T4
ligase. The 4C material was ethanol precipitated and column purified using Zymo
Research DNA concentrator kit. 150 uL 10 mM Tris-HCL (pH 8.0) was used to elute
DNA.
4C viewpoint primers were selected from human Nla3-Dpn2 primer pair database
provided by Tayan’s group (http://compgenomics.weizmann.ac.il/tanay/?page_id=367).
Primer pair sequences and illumina adapters are listed in table 4. Sequential PCR
using Expand Long Template Polymerase (Roche) was performed to construct 4C
library. Genomic primer pairs of 4C viewpoints were used for the first PCR, and the
products were purified by Zymo Research DNA concentrator kit. The PCR products
were eluted in 10 mM Tris (pH 8.0) as the template for the second PCR using Illumina
barcoded adapters as primers. All PCR reactions were done in 8 replicates. 2 nM 4C
library from each sample was pooled together before loading on the Illumina NextSeq
500. r3Cseq R package was used to analyze the data (93). All sample were done in
replicates.

RNA isolation and qRT-PCR
RNA was isolated using RNA Bee following the manufacture’s instructions. 1 ug of RNA
was used for reverse transcription using BioRad iScript Advanced cDNA Synthesis Kit.
30 ng of cDNA was loaded in a 20 uL qPCR reaction. qPCR was performed using
BioRAd CFX Touch Real-Time PCR Detection System. Relative expression was
calculated using delta delta Ct method.
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Neural differentiation
iPSC-derived 10 wk neurons were differentiated using monolayer protocol as described
(70). Briefly, 2-day post split iPSCs were switched to N2B27 medium supplemented
with 500 ng/mL Noggin (R&D Systems) for 14 days with a complete change of medium
every other day. Colonies were split on to poly-ornithine and laminin-coated plates with
1:2 ratio using StemPro EZ Passage tool (Life Technologies) for another week with a
complete change of medium every other day. These cells were trypsinized and replated
to poly-ornithine and laminin-coated plates and supplemented with ROCKi overnight.
Cells were kept in N2B27 for a few more days before switching to neural differentiation
medium for a week. These cells can be plated for terminally differentiated neurons at
the density of 200,000 cells per well of a 6 well plate. Cells were kept in neuron
differentiation medium for another 5 week to obtain electrophysiological mature neurons
for experiments.

Results
CTCF binds in an allele- and tissue-specific manner across the imprinted region
of 15q11-13
To test our previous speculation that CTCF at PWAR1 may be involved in
stopping the distal portion of SNURF/SNRPN transcript, we examined allelic distribution
of the binding by ChIP-seq using paternal-allele only AS-iPSCs and maternal-allele only
PWS-iPSCs. We found that CTCF preferentially binds to the paternal allele throughout
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the imprinted region from MKRN3 to UBE3A whereas the maternal counterpart did not
show CTCF binding (Fig 1A). Notably, the binding is bi-allelic outside the imprinted
region (Fig 1A). We confirmed the allele-specific CTCF binding by ChIP-qPCR on 3
sites. Two of them, SNRPN_U and PWAR1, are located within the imprinted region,
and another, UBE3A_U, is located outside of the imprinted region. CTCF binding is
enriched at SNRPN_U and PWAR1 on the paternal allele, whereas UBE3A_U did not
show allelic preference (Fig 1B). Upon neural differentiation, CTCF binding was lost at
PWAR1 and SNORD116 sites (Fig 1C) but not at SNRPN_U and UBE3A_U sites (Fig
1D). CTCF preferentially binds to the active paternal allele across the imprinted
domain. In neurons, reduced binding of CTCF at PWAR1, allows transcription to pass
through and expresses the distal portion of SNURF/SNRPN transcripts. Loss of CTCF
binding at PWAR1 during neural differentiation supports our hypothesis that CTCF
binding at PWAR1 is involved in stopping transcription in iPSCs and other non-neuronal
cell types.

CRISPR-mediated 24 kb deletion identifies the critical region regulating UBE3AATS expression
The region that separates the distal portion of SNURF/SNRPN lncRNA from the
proximal portion of it is consist of a cluster of CTCF binding at PWAR1 as well as a
stretch of weak poly-A sites at IPW (Fig. 2A). RNA polymerase II (RNAPII) was shown
to accumulate near CTCF binding sites at PWAR1 in human embryonic stem cells (H1ESC), suggesting that CTCF is blocking RNAPII from further transcribing. RNA-seq
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data from ENCODE showed that majority of RNA is terminated at IPW, and completely
stopped at PWAR1 (Fig 2A). Moreover, several atypical paternal deletions missing
these two potential transcription termination signals showed the distal portion of
SNURF/SNRPN transcripts including SNORD115 and SNORD109B. As a result, we
hypothesized that this 24 kb region containing poly-A signal and CTCF binding is critical
for regulating the distal portion of SNURF/SNRPN, including SNORD115 and UBE3AATS. We deleted this region in AS iPSCs where there is only the active
SNRUF/SNRPN allele. Two separate approaches were used to generate the deletion in
one experiment. First, a pair of CRISPRs flanking IPW to PWAR1 was designed to
make the deletion (ΔI-P). Second, two single stranded oligonucleotides (ssODNs) were
designed as homologous templates to insert loxP sequence at the cut sites. All 4
components were electroporated in AS iPSCs and 96 clones were screened. We
obtained 7 deletion clones and 1 clone with loxP inserted at both cut sites. The loxP
sites were recombined by Cre-recombinase to create the 24 kb deletion. We picked two
clones from CRISPR-mediated deletion and two clones from Cre-mediated deletion for
data analysis. Upon removal of the region, we detected the expression of SNORD115
(Fig 1B), suggesting that this IPW to PWAR1 region is critical in controlling the distal
portion of SNURF/SNRPN lncRNA.
To rule out the possibility that the 24kb deletions disrupted transcription from the
SNURF/SNRPN promoter, we examined the expression of SNRPN and SNORD116,
two of the proximal portion of SNURF/SNRPN transcripts. Our data also showed that
SNRPN and SNORD116 remained the same across all deletion clones (Fig 2C),
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suggesting that expression of SNORD115 is not due to up-regulation from the
SNURF/SNRPN promoter.

IPW and PAR1 comprise a bipartite transcriptional boundary
To decipher individual functions of IPW and PWAR1, we deleted PWAR1 (ΔP)
(~7kb) and IPW (ΔI) (~5kb) in AS iPSCs separately (Fig 3A). In ΔP clones, we
observed minimal expression of SNORD115 (Fig 3B). In ΔI clones, the SNORD115
expression was detected at 50% of SNORD115 expression levels seen in ΔI-P clones.
This indicated that the two components work together to comprise the boundary
function. To rule out the possibility that sequences in between these two components
may play a role in stopping transcription, we deleted IPW and PWAR1 sequentially,
(ΔIΔP) leaving the sequence in between intact (Fig 2A). The expression of SNORD115
in ΔIΔP clones was almost identical to that in ΔI-P clones (Fig 2B). This suggested that
IPW and PWAR1 are the pivotal elements in stopping the distal portion of
SNURF/SNRPN transcript.

The boundary function of IPW and PWAR1 is directional
Both CTCF-mediated looping function and poly-A signal-mediated transcriptional
termination are known to be directional. To test whether we can disrupt their function by
inverting the sequence, we generated an IPW-PWAR1 inversion clone (INV) using the
same pair of CRISPRs for ΔI-P (Fig 3A). We did not detect SNORD115 expression in
the inversion clone (Fig 3A), indicating the function of the inverted boundary is not
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disrupted. To dissect the individual role of the inverted IPW and PWAR1, we deleted
them separately (Fig 3A) in an INV clone. Although IPW was shown to be the more
important component of the boundary component of the two, we did not detect any
SNORD115 when the inverted IPW was deleted (INVΔI) (Fig 3B). This suggested that
the inverted IPW loses its function to stop transcription, perhaps due to the directionality
of polyadenylation sequence. Surprisingly, when the inverted PWAR1 region was
deleted in the inversion line (INVΔP), SNORD115 was detected (Fig 3B), suggesting
that the inverted PWAR1 has a gain-of-function property sufficient to stop transcription.
Notably, SNORD115 expression in this line is about 40% of that in ΔI-P lines (Fig 3B),
indicating the inverted IPW sequence may still function to interrupt transcription. As a
result, we sequentially deleted the inverted IPW in the INVΔP line (INVΔPΔI). Although
there was a slight increase in SNORD115 expression, it was not close to the level in ΔIP or ΔIΔP lines.
To further demonstrate the directionality of IPW and PWAR1 in stopping
transcription, we generated 2 additional inversions. First, we flipped the inverted IPW
back to its natural orientation in INVΔP line (INVΔP_INV-I) (Fig 3C). This allowed us to
demonstrate that IPW in the proper orientation works as a transcriptional block. Indeed,
SNORD115 in INVΔP_INV-I clone was dropped down to almost baseline,
demonstrating the importance of its orientation (Fig 3D). Second, we inverted PWAR1
in ΔI line (ΔI_INV-P) (Fig 3E). This allowed us take another approach to determine
whether inverted PWAR1 had a gain-of-function. SNORD115 in these clones showed
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50% reduction compared to its parent line, suggesting that inverted PWAR1 has a gainof-function property (Fig 3F).

Shortening the distance between SNURF/SNRPN promoter and UBE3A resulted
in fully imprinting of UBE3A
It is thought that UBE3A is imprinted when the distal portion of SNURF/SNRPN
RNA that encompasses UBE3A-ATS is transcribed. However, UBE3A imprinting was
not observed in ΔI and ΔI-P clones where UBE3A-ATS is transcribed (Fig 4B). We
previously reported 80% imprinting of UBE3A in PWS iPSCs with an atypical deletion
when the paternal SNURF/SNRPN promoter drives the expression of the distal portion
of the transcript directly. However, roughly 20% of cells showed some level of UBE3A
expression by FISH and by strand-specific RT-PCR. We speculated that cell division
occurs before UBE3A is imprinted by UBE3A-ATS. To address this question, we
deleted the region from SNURF/SNRPN intron 1 to SNORD115-47 (ΔS-115) in AS
iPSCs (Fig 4A). This 303 kb deletion shared the same 5’ end of PWSSD, but with the 3’
end 110 kb close to UBE3A gene body. This should eliminate the possibility that cell
division takes place before imprinting of UBE3A. Indeed, UBE3A is completely
imprinted in these clones suggesting that shortening the distance between
SNURF/SNRPN promoter to UBE3A affects the level of UBE3A imprinting (Fig 4C).

Early imprinting of UBE3A occurs when the boundary is removed

	
  

60	
  

We previously showed that UBE3A is imprinted in non-neurons when UBE3AATS is transcribed. Here, we showed that deletion of boundary element leads to
expression of UBE3A-ATS transcript. However, imprinting of UBE3A did not occur. We
hypothesized that imprinting of UBE3A requires higher level of UBE3A-ATS. In
addition, upstream exons of SNRPN have been hypothesized to drive SNURF/SNRPN
lncRNA expression during neural differentiation, increasing the level of antisense
transcripts. Therefore, we differentiated the ΔI-P line along with the unmodified AS
iPSC as control. The time course showed that SNORD115 expression only increases in
10wk neurons in the unmodified control whereas the expression from the ΔI-P line
already exceeds it at 4wk and remains high afterwards (Fig 4D). More importantly,
UBE3A starts to show imprinting at 4wk and remained down at 10wk after neural
differentiation (Fig 4E). This suggested that higher level of transcription from the
antisense direction is absolutely critical to silence UBE3A. However, UBE3A is not
completely abolished. It is possible that the some of the UBE3A-ATS transcription
machinery does not reach to UBE3A due to massive RNA processing in this region.

Imprinting of UBE3A does not take place in the boundary-inverted neurons
The inverted boundary in INV still functions as a boundary to stop transcription
(Fig 3B). SNORD115 is expressed at a higher level at earlier time points compared to
unmodified control (Fig 4D). Interestingly, the SNORD115 expression remains about
the same level at 10 wk whereas that of the unmodified control increases dramatically at
10 wk (Fig 4D). This suggests that although the inverted boundary loses its function to
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entirely stop the transcription during earlier stages of neural differentiation, at later
stages, the inverted boundary cannot be released. Thus, imprinted expression of
UBE3A is not seen in INV neurons. This is most likely due to gain-of-function of the
inverted PWAR1 because it reduced SNORD115 expression in the IPW deletion line
when PWAR1 is inverted (Fig 3E).

3D chromatin interaction does not change between iPSCs and neurons
CTCF is a well-known chromatin architectural protein that creates stable 3D
looping structure for chromosome integrity. CTCF ChIP-seq and ChIP-qPCR data
showed that CTCF remains bound at two sites outside of the critical SNRPN-UBE3A
imprinting region while majority of CTCF binding sites within this region were lost during
differentiation, including the binding at PWAR1. We hypothesized that SNRPN_U,
PWAR1, and UBE3A_U forms a CTCF-mediated loop in iPSCs. In neurons, PWAR1 is
no longer attached to this loop allowing the transcript to pass through. To test this
hypothesis, we utilized circularized chromosome conformation capture followed by
sequencing (4C-seq) to determine all the interactions loci with our viewpoints
(SNRPN_U, UBE3A_U, and PWAR1). Indeed, SNRPN_U and UBE3A_U showed very
strong interactions in both iPSCs and neurons (Fig 5A). PWAR1 is also part of this
chromatin hub, but the interaction does not change between iPSCs and neurons as we
hypothesized (Fig 5A). Notably, PWAR1 interaction can only be detected when
UBE3A_U is used as the viewpoint (Fig 5A). It is not detected by SNRPN_U viewpoint,
suggesting that there is steric hindrance between PWAR1 and SNRPN_U although they

	
  

62	
  

are in close proximity (Supplementary Fig 1). Interestingly, PWAR1 seems to be very
constrained in its own territory because most of its interactions are nearby
(Supplementary Fig 2). The aforementioned viewpoints did not show any interactions
different between iPSCs and neurons, suggesting that this chromatin structure is very
stable across different cell types (Fig 5A, Supplementary Fig 1,2). Thus, altered
chromatin looping is unlikely to contribute to gene expression changes during
neurogenesis.

IPW showed subtle increase in interactions during neural differentiation
When IPW is used as the viewpoint, the majority of interactions are locally with
the exception of SNRPN_U in iPSCs (Supplementary Fig 3). In neurons, the local
interaction reduces and there are increase frequency of interactions around SNRPN and
SNORD116 loci (Supplementary Fig 3). These data suggest that a stable SNRPNUBE3A loop structure exists regardless of the cell type. IPW and PWAR1 are spatially
involved in this loop where IPW is in close proximity with SNRPN_U and PWAR1 is in
close proximity with UBE3A_U. During neural differentiation, IPW locus is no longer
constrained allowing transcription machinery to continue transcribing the neuron-specific
transcript.

Discussion
We use CRISPR/Cas9 to generate site-specific deletions to understand the
mechanism by which UBE3A-ATS is regulated. We show that UBE3A-ATS expression
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is controlled by a bipartite boundary consisted of IPW and PWAR1 in iPSCs. When the
entire region is missing, the distal cluster of SNURF/SNRPN lncRNA is expressed
including SNORD115 and UBE3A-ATS. We further dissect the individual function of
IPW and PWAR1. We speculate that polyadenylation sites at IPW are the major
transcription terminator. When IPW is missing, transcription is not actively terminated
and SNORD115 is detected. However, the level of SNORD115 is only half compared to
the deletion of entire IPW to PWAR1. This suggests that PWAR1 interferes with
transcription by blocking RNAPII when IPW loses its function. Taken together, these
two transcriptional boundary elements work together to block RNAPII from going further.
We sought to disrupt the boundary by inverting the region. To our surprise, the
inverted sequence still functions as the boundary since no SNORD115 expression was
detected. We further dissected the function of the inverted IPW and PWAR1
individually. Deleting the inverted IPW did not disrupt the boundary function.
Interestingly, deleting the inverted PWAR1 disrupted the boundary function as the
SNORD115 expression was detected. The inverted PWAR1 showed gain-of-function
whereas the inverted IPW showed loss-of-function in terms of their ability to act as
transcription terminators. To further demonstrate the boundary function of IPW and
PWAR1 is directional, we inverted IPW back to its natural sequence in the inverted cell
line where PWAR1 is deleted. SNORD115 expression was no longer detected. We
demonstrated the gain-of-function of PWAR1 by inverting PWAR1 in the cell line where
IPW is deleted. SNORD115 is significantly reduced. It has been reported that the
direction of CTCF binding determines the looping structure. The inverted CTCF binding
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at PWAR1 potentially gains new interactions and the interactions interfere with
transcription. To sum up, our data suggested that the transcriptional termination
function of IPW and PWAR1 are directional.
We previously reported that imprinting of UBE3A occurs in non-neuronal cells
when UBE3A-ATS is actively transcribed. However, imprinting of UBE3A was not
observed in the boundary deleted cell lines where UBE3A-ATS is expressed. We
speculated that there is not enough transcription going through UBE3A gene body to
imprint UBE3A. We demonstrated that imprinting of UBE3A depends on the level of
transcriptional events from the antisense direction in two ways. First, we generated a
paternal deletion that spans from SNURF/SNRPN intron 1 to SNORD115-45, 116 kb
larger than the PWS SD to achieve complete imprinting of UBE3A. UBE3A-ATS is
transcribed strongly from the promoter without the massively processed SNORD116
and SNORD115 regions. UBE3A is completely imprinted in this 303 kb deletion line.
Second, imprinting of UBE3A is achieved by differentiating the boundary-deleted iPSCs
into neurons. It is known that usage of the SNURF/SNRPN upstream exons occurs in
neurons, and switches the expression from the coding portion of SNURF/SNRPN to the
non-coding portion. This increases the total amount of UBE3A-ATS transcription during
neural differentiation. Early imprinting of UBE3A was observed in the boundary-deleted
neural progenitors, and the imprinting maintained in neurons.
CTCF binding at chromosome 15q11-13 exhibits allele-specificity and tissuespecificity. CTCF binds to the paternal allele throughout the imprinted region. The
allele-specific binding does not present outside of the imprinted region. Moreover, most
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of the CTCF binding in the imprinted region is lost in neurons including the binding at
PWAR1. However, a few invariant sites showed no tissue-specificity. The variant and
invariant binding of CTCF between iPSCs and neurons led us to propose that CTCF
mediates different chromatin structure between cell types. Moreover, it has been
reported that SNRPN to UBE3A region undergoes chromatin decondensation (94, 95).
Our 4C data showed that a stable interaction exists between upstream of SNRPN and
upstream of UBE3A. PWAR1 is also involved in the hub. This interaction, however, is
not different between iPSCs and neurons. Lost of CTCF at PWAR1 in neurons does not
alter the interaction, suggesting that the participation of PWAR1 in the loop is probably
CTCF independent.
Altogether, we discovered minimal required regions that regulate UBE3A-ATS.
They are comprised of IPW and PWAR1 that act together as a transcriptional terminator
to stop transcription. Both IPW and PWAR1 work in an orientation-specific manner,
perhaps due to the mechanism by which transcription is terminated or interrupted. We
also demonstrated that upstream of SNRPN and UBE3A forms a stable interaction that
is indifferent between cell types. These findings provide essential information on how
the UBE3A-ATS is regulated. Several reports have focused on awakening the dormant
UBE3A by blocking UBE3A-ATS as a treatment for AS. Potential therapies can be
developed by interfering with the transcriptional terminator to achieve the goal to
reactivate the dormant UBE3A.
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qRT-PCR of SNORD115 in the IPW-PWAR1 deletion lines. C. qRT-PCR of SNRPN
and SNORD116 in the IPW-PWAR1 deletion lines. qRT-PCR was done in biological
triplicates.

	
  

69	
  

A

B
IPW

SNORD115

PWAR1
Ctrl (AS iPSC)
I-P_1
I-P_2
P_1
P_2
I_1
I_2
I P_1
I P_2
INV
INV I_1
INV I_2
INV P_1
INV P_2
INV I P_1

1RAWP

INV I P_2

WPI

0.00

C

50.00

100.00
150.00
Relative Expression

50.00

100.00
150.00
Relative Expression

50.00

100.00
150.00
Relative Expression

200.00

D
Ctrl (AS iPSC)

1RAWP

INV

WPI

INV P_1
INV P_INV-I_1
INV P_INV-I_2

IPW

0.00

200.00

F

E
IPW

PWAR1

Ctrl (AS iPSC)
I_1
I_INV-P_1
I_INV-P_2

1RAWP

0.00

200.00

Figure 3. IPW and PWAR1 comprise the bipartite boundary and their functions
are directional. A,C,E. Schematic illustrations showing various deletion lines
engineered. Yellow color indicates 5’ and black color indicate 3’ of the original

	
  

70	
  

orientation. B,D,F. qRT-PCR of SNORD115 in various genome-engineered lines of
IPW-PWAR1 region. qRT-PCR were done in triplicates.
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red lines denote inversion line, and green lines denote IPW-PWAR1 deletion line. All
qRT-PCR were done at least in biological triplicates.
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Table 1. qPCR primers for ChIP
Primer name
SNRPN_U_F
SNRPN_U_R
PAR1_F
PAR1_R
UBE3A_U_F
UBE3A_U_R
SNRPN_exon_F
SNRPN_exon_R
SNORD116_F
SNORD116_R
PAR1_mi_F
PAR1_mi_R

	
  

sequence
GGTCTCTCAGTTGGCTCCTG
ATGGTGGATACTTGGCTTGG
CAGGGAACGCTCTTCAACAT
AACCAGTTCCAAACCTGACG
TGCTTCTGAACCCTGAATCC
CATGGACAAGTGTGTGTTGCT
ATCTGTCTGAGGAGCGGTCAGT
TCCCCAGGCTGTCTCTTGAG
GTTGGTGTTGCCTAGCATCC
CCTTGCAGGTCTTGGAAATC
CAGGGAAAGGGAGTTTGTTG
CGTGGGATTGTTTGATAGTGTG
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Table 2. CRISPR sequences for genome manipulation
CRISPR name
IPW 5’ #1
IPW 5’ #2
IPW 5’ #4
IPW 3’
PAR1 5’
PAR1 3’
SNRPN_intron 1
SNORD115-45

	
  

sequence
TATACAGAGCAATACGATCA
GGAAAGGTTGGATTAAACTA
TCTAAGAATTCCACTGGTGA
AACTAGCACATACAAGGAAC
GTTCTGAAGCAAGGTATACC
ATATAACCAAATTGTCCGTT
CAAGAACCTGGCATATACGA
GACTCCATAGATTAACCCCC
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Table 3. PCR primers for clone-screening
Primer name
IPW_T1
IPW_T2
IPW_T3
IPW_T4
PAR1_T1
PAR1_T2
PAR1_T3
PAR1_T4
PAR1_T4’
SNRPN_intron_T1
SNORD115-45_T4
IPW_F
IPW_R
PAR1_F
PAR1_R
PAR5_F
PAR5_R

	
  

sequence
TTGCACATAAATATTGCCTTTCA
ACTGCCCTCCCTTTACCCTA
CTAGCCTTCCCCTTCCATCT
TGGGAGAATAAGAAGCGTTAAGA
CCTCCCTCAAATTGCTCTTTT
TTGTGCAAATGCAATATGTGA
TCATATACGAGTTGAGTCCCAAT
TGGTCTTTGGAAGGAGATGG
TGTTTTAATCTGCGTCCTTTTG
GCTGAAAGACATTCGTTTGGA
CGCCACAATGGTGTCTTTTT
TCTTCTGCCTCCTGTCTCGT
TCCCATCACCACAGTGAAAA
CAGGGAACGCTCTTCAACAT
AACCAGTTCCAAACCTGACG
AGGTGCTTTTGCTTTGCCTA
TCTCTGAACCCCAACAGCTT
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Table 4. 4C viewpoint primers for 4C-seq library preparation
Genomic primer
SNRPN_U_NlaIII
IPW_NlaIII
PWAR1_NlaIII
UBE3A_U_NlaIII
SNRPN_DpnII
IPW_DpnII
PWAR1_DpnII
UBE3A_U_DpnII

sequence
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCATAAGAAGTTGAAGCATG
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTTTCTGGGAGAAGCCATG
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATATGCCCACATTCCACATG
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTTGGATACCTTTCATCATG
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAGTTGGCTCCTGTATCATT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCATAACCATCTAGTCCACAA
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGCCCCAGGGAAAATAGTACC
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTACTGTGGGTTTTTGGTTTT

Table 5. Illumina HT adapter primers for 2nd PCR
Illumina HT adapters
Truseq_HT_D504
Truseq_HT_D505
Truseq_HT_D506
Truseq_HT_D507
Truseq_HT_D705_r
evcom
Truseq_HT_D706_r
evcom
Truseq_HT_D707_r
evcom

	
  

AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACG
ACGCTCTTCCGATCT
AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACG
ACGCTCTTCCGATCT
AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGA
CGCTCTTCCGATCT
AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACG
ACGCTCTTCCGATCT
CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGC
TCTTCCGATCT
CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT
CAAGCAGAAGACGGCATACGAGATCTGAAGCTGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT
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4. Chapter 4
Using AS iPSC-derived neurons as a tool to screen for drugs capable of
unsilencing the dormant paternal UBE3A

Data presented in this chapter are published in the following paper
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Introduction
Topoisomerase inhibitors can transcriptionally un-silence the paternal allele of
Ube3a in mouse cortical neurons (26). Ube3a is located adjacent to a cluster of
imprinted genes, is normally expressed only from the maternal allele in neurons, and
regulates synaptic function. In humans, UBE3A is associated with two distinct
neurodevelopmental disorders. Specifically, deletion or mutation of maternal UBE3A
causes Angelman syndrome, whereas duplication of the chromosomal region containing
maternal UBE3A is frequently detected in individuals with autism (5). Although
topoisomerase inhibitors can un-silence the dormant allele of Ube3a in mouse, the
effect of topoisomerase inhibitors need to be tested in human. Here, we show that
topoisomerase inhibitors downregulate UBE3A-ATS and unsilence the paternal UBE3A
in human iPSC-derived neurons. Similar to mouse neurons, the effect of topoisomerase
inhibitors is on extremely long genes involved in synaptic functions. In addition, many of
these genes are listed as autism spectrum disorder (ASD) candidate genes.

Materials and Methods
iPSC culture and neuronal differentiation
Human iPSC work was approved by the University of Connecticut Stem Cell Research
Oversight Committee. iPSCs that carry a large deletion of maternal 15q11-13 were
cultured on irradiated mouse embryonic fibroblasts and manually passaged as
described (10). This cell line (AGdel1-0) was deemed exempt from IRB approval at the
University of Connecticut due to its establishment in 1995 and lack of identifying
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information. iPSCs were differentiated into forebrain cortical neurons as described (10)
with the following modifications: neural progenitors were generated by culturing iPSCs
on feeders in N3B27 medium supplemented with noggin (500 ng/ml) for 8 days and then
manually picking neural rosettes for two additional passages using trypsin and standard
cell culture protocols. Topotecan was applied to mature neurons and RNA was
collected by standard protocols 6 days after the addition of drug of vehicle.

qRT-PCR
It was carried out as descried using Taqman (Life Technologies) gene expression
assays for UBE3A (Hs00166580_m1) and UBE3A-ATS (Hs03454279_m1) according to
the manufacturer’s instructions. The Taqman assay for GAPDH was used as a control.

RNA-seq
Total RNA was collected as previously described (10). Standard multiplexed mRNA
libraries were prepared using Illumina kits. Cluster generation and sequencing were
performed using Illumina HiSeq 2000 platform. Reads were aligned using Bowtie.
Read counts were obtained using DEGseq, and normalization and analysis of
differential gene expression was performed using the R package, edgeR, using a
negative binomial model.

Results
Topotecan has the similar transcriptional effect on both mouse and human
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Ube3a-ATS/UBE3A-ATS
As founded previously, topotecan reduced the expression of an extreamly long (>
1 megabase), paternally expressed antisense transcript that overlaps Ube3a (Ube3aATS) (26). The Ube3a-ATS is required for paternal Ube3a silencing (72, 96). Notably,
topotecan also reduced the expression of UBE3A-ATS and increased the expression of
UBE3A in iPSC-derived neurons from an AS patient (Fig 1). Topotecan thus had similar
transcriptional effects at the Ube3a locus in mouse and human neurons.

Topetecan reduces expression of long genes in neurons
Because Ube3a-ATS is extremely long and was strongly downregulated, we
hypothesized that topotecan might reduce the expression of other long genes. RNAseq and Affymetrix microarrays data showed that topotecan reduced the expression of
nearly all extremely long genes in mouse cortical neurons (Fig 2 A-C), with a strong
correlation between gene length and reduced expression (for genes longer than 67
kilobases (kb); Pearson’s correlation coefficient (R) = -0.69). Topotecan also reduced
the expression of long genes in iPSC-derived human neurons (Fig 2D). Specifically, the
percentage of genes that were inhibited (to any extent) by 300 mM topotecan increased
from 50% for genes 67 kb in length to nearly 100% for genes ~200 kb and longer. In
addition, inhibition of long genes by topotecan was highly dose dependent (Fig 3).

Numerous Autism Spectrum Disorder (ASD) genes are affected
To investigate further the biological consequences of topotecan treatment in
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neurons, we defined a list of genes that were differentially expressed with high
confidence. From RNA-seq expression data, we found that topotecan significantly
downregulated 155 genes and significantly upregulated 28 genes. The topotecandownregulated genes were significantly longer than all expressed genes in cortical
neurons, further suggested that topotecan has pronounced effects on long genes. On
the basis of Gene Ontology and functional annotation terms, we found that many
topotecan-downregualted gene were involved in neuronal development and synaptic
function. Because ASD is thought to be a neurodevelopmental disorder that affects
synapses, we cross-referenced out list of downregulated genes with know ASD
candidate genes, combining genes in the SAFRI Gene database with candidates
identified in recent exome sequencing studies (97–101). 27% of the 183 differentially
expressed genes are known ASD candidate genes (Table 1), a proportion that is highly
significant compared to chance.

Discussion
We show AS iPSC-derived neurons can be a great tool to screen for compounds
that unsilence the dormant UBE3A. The finding also suggested that the underlying
mechanism by which Ube3a-ATS/UBE3A-ATS silences Ube3a/UBE3A are very similar
between mouse and human neurons. It is striking that topoisomerase inhibitors affects
extremely long genes, and many of those genes are listed as ASD genes.
Topoisomerase was the first compound shown to reactive the silent Ube3a/UBE3A (26).
However, its application of being a therapy for AS requires more intensive studies as it
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affected so many other genes involved in synaptic functions in the brain. A recent study
using antisense oligo to specific downregulate Ube3a-ATS in mouse neuron
demonstrated more potential as a therapy (27). Nonetheless, it needs to be tested in
human neurons to show its efficacy to unsilence the dormant paternal allele.
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Figure 1. Topotecan reduces UBE3A-ATS and reactivates UBE3A expression in
AS iPSC-derived neurons. Expression of UBE3A and UBE3A-ATS in iPSC-derived
neurons from an Angelman syndrome patient carrying a maternal deletion of the 15q1113 region. Differentiated neuronal cultures were treated with 10 nM-10 uM topotecan or
vehicle for 6 days. Expression quantified by qPCR. **P < 0.01, one-way analysis of
variance with Dunnet’s post-hoc test. n = 4. Error bars represent s.e.m.
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Figure 2. Topotecan reduces expression of long genes in neurons. A. Mouse
cortical neurons treated with vehicle (v) or 300 nM topotecan (drug; d) for 3 days (n = 5
biological replicates). RNA-seq gene expression versus gene length. B. Mean
expression change in bins of 200 genes by length. C. Percentage of genes that were
reduced in expression by topotecan; plotted as a sliding window of 100 genes by length,
RNA-seq data (log scale). Inset, same data on linear scale. D. iPSC-derived human
neurons treated with 1 uM topotecan for 6 days relative to vehicle, RNA-seq data in bins
of 200 genes by length (n = 2 biological replicates).
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Figure 3. Topotecan dose-response. Mouse cortical neurons were treated with 3 nM,
30 nM, 150 nM, 300 nM and 1000 nM topotecan for 3 days (n=3 for 300 nM topotecan,
all other doses n=1). Gene expression was analyzed by Affymetrix microarrays, plotted
as mean expression change in bins of 200 genes.
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Table 1. Topotecan reduces expression of numerous ASD candidate genes in
neurons
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5. Chapter 5
Significance and Future directions
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The discovery of iPSC as a model to study human diseases has a fundamental
impact on biological research. Specifically, it has re-shaped the research on human
neurological disorders. With the previously developed neural differentiation protocols
from stem cells, understanding neurogenetic disorders during development has never
been easier. Researchers can acquire somatic cells from individuals with disorders and
reprogram the cells into iPSCs for neural differentiation to study the differences between
normal and disease states. Numerous reports of disease-modeling using iPSCs have
been published, including our diseases of interest. The recent discovery of
CRISPR/Cas9 in which genome can be manipulated in a site-specific manner changes
the field of biological research once more. This technology has brought so much
potential not only to basic research, but also to genetic medicine. We took advantage of
both technologies and applied it to understand the regulation of UBE3A-ATS and
imprinting of UBE3A in the context of AS.
My main research goal focused on identifing the mechanism by which UBE3AATS is regulated. Understanding the regulation of UBE3A-ATS allows us to intervene
its process as a new approach to unsilence the paternal UBE3A. We first noticed a
PWS patient who has a very unique deletion paternally-inherited allele. We acquired
fibroblasts from this individual and reprogramed to iPSCs. Our data agreed with the
reported article that neuron-specific UBE3A-ATS is expressed in non-neurons. We
further discovered that imprinting of UBE3A does not require any neuronal factors and
hypothesized that a region encompasses a stretch of polyadenlyation sequences as
well as a cluster of CTCF binding sites is the key to UBE3A-ATS regulation. In order to
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prove our hypothesis, we utilized CRISPR/Cas9 to delete regions in AS iPSCs where
paternally-inherited allele is the only allele present. After examining the SNORD115
expression in many deletion lines, we discovered that ~5kb region of IPW that contains
polyadenylation sites and ~7kb region of PWAR1 that contains a cluster of CTCF
binding sites are absolutely essential to control the UBE3A-ATS expression.
We also discovered that the imprinting process of UBE3A during neuronal
differentiation is disrupted when the critical region is inverted. Although UBE3A-ATS is
transcribed in the boundary inverted cell line, its level is not sufficient to imprint UBE3A.
Furthermore, we discovered that imprinting of UBE3A is dependent on the level of
UBE3A-ATS transcribed. We do not know if the transcribed RNA that is essential to
silence UBE3A, or the active transcribing RNAPII going through UBE3A gene body that
is required to silence UBE3A. More experiments need to be done to unravel the
mechanism. GRO-seq, a nuclear run-on assay that determines the location of a
transcribing RNAPII at a certain time point, is the technique useful to identify where the
UBE3A-ATS and UBE3A collide. We generated a cell line with the expression of
UBE3A-ATS but no imprinting of UBE3A. We also generated a cell line with the
expression of UBE3A-ATS and imprinting of UBE3A. These two cell lines are useful for
studying where RNAPII collides.
The tissue-specific CTCF binding at PWAR1 led us to hypothesize that CTCF acts
as a boundary in non-neurons to stop transcription, whereas in neurons, the binding is
lost allowing transcription to continue and imprints UBE3A. However, deletion of
PWAR1 in AS iPSC did not support this hypothesis. We did not observe any
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reactivation of SNORD115 nor UBE3A-ATS in these engineered cell lines. The binding
of CTCF occurs throughout the paternal allele of the chromosome 15q11-13. The
tissue-specific binding pattern of CTCF is also observed on many of the binding sites.
This binding pattern between iPSCs and neurons led us to re-hypothesize that there are
tissue-specific differences of CTCF-mediated looping structure during neural
differentiation. The change in looping structure contributes to the neuron-specific
UBE3A-ATS expression. Indeed, we identified a looping structure at the imprinted
SNRPN to UBE3A region. PWAR1 is also involved in this loop. However, the loop
structure does not change during neural differentiation. This indicates that regulation of
UBE3A-ATS does not result from changes in chromatin structure. Nonetheless,
PWAR1 region in clearly involved in participating transcription interference. When
PWAR1 region is present in the IPW deleted line, UBE3A-ATS level is only half of that
in the IPW and PWAR1 deleted line. When PWAR1 region is inverted, it alone is able to
stop the transcript. It is possible that proteins other than CTCF bound at PWAR1 region
are involved in the transcription termination process.
In summary, iPSC is a great tool for disease modeling and drug screening as
described in various chapters. In combination with the CRISPR/Cas9 gemone-editing
tool, we have made a huge break through in terms of UBE3A-ATS regulation as well as
UBE3A imprinting. We showed that genomic region of IPW and PWAR1 are essential
for UBE3A-ATS regulation, and their transcriptional termination functions are directional.
However, more experiments need to be done to decipher what the essential element(s)
is/are in the process of stopping transcription within IPW and PWAR1 region. In
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addition, imprinting of UBE3A is not a simple process by having its reciprocal UBE3AATS. Imprinting either requires a substantial amount of UBE3A-ATS transcribed, or the
substantial transcription units from the antisense direction colliding with that from the
sense direction. Although we have achieved identifying the fundamental components
that regulate UBE3A-ATS, there remain many questions to be answered. Continuing
this research will give hopes to the AS individual and their families that one day, we will
develop therapies to help them improve their life.
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